TY  - JOUR
AU  - Perovnik, Matej
AU  - Simončič, Urban
AU  - Jamšek, Jan
AU  - Gregorič Kramberger, Milica
AU  - Brumberg, Joachim
AU  - Meyer, Philipp Tobias
AU  - Perani, Daniela
AU  - Caminiti, Silvia Paola
AU  - Brendel, Matthias
AU  - Stockbauer, Anna
AU  - Camacho, Valle
AU  - Alcolea, Daniel
AU  - Vandenberghe, Rik
AU  - Van Laere, Koen
AU  - Ko, Ji Hyun
AU  - Lee, Chong Sik
AU  - Pardini, Matteo
AU  - Lombardo, Lorenzo
AU  - Padovani, Alessandro
AU  - Pilotto, Andrea
AU  - Ochoa-Figueroa, Miguel A
AU  - Davidsson, Anette
AU  - Cháfer-Pericás, Consuelo
AU  - Álvarez-Sánchez, Lourdes
AU  - Garibotto, Valentina
AU  - Lemstra, Afina W
AU  - Ferreira, Daniel
AU  - Morbelli, Silvia Daniela
AU  - Tang, Chris C
AU  - Eidelberg, David
AU  - Trošt, Maja
TI  - Metabolic brain networks in dementia with Lewy bodies: from prodromal to manifest disease stages.
JO  - Journal of neurology, neurosurgery, and psychiatry
VL  - 97
IS  - 4
SN  - 0022-3050
CY  - London
PB  - BMJ Publishing Group
M1  - DZNE-2026-00296
SP  - 316 - 324
PY  - 2026
AB  - Dementia with Lewy bodies (DLB) is the second most common neurodegenerative dementia, yet it remains under-recognised and misdiagnosed, which delays treatment, causes inaccurate prognosis and limits research opportunities. Imaging with 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) is a supportive DLB biomarker. We evaluated a multivariate, quantifiable metabolic network biomarker, termed DLB-related pattern (DLBRP), for its further clinical translation across centres and disease stages.We analysed demographic, clinical and FDG PET imaging data of 1180 participants from 14 tertiary centres and two multicentre datasets. We included 379 DLB, 28 mild cognitive impairment-LB (MCI-LB), 195 dementia due to Alzheimer's disease (ADD), 172 MCI-AD without α-synuclein co-pathology (MCI-AD-S-), and 73 MCI-AD with α-synuclein co-pathology (S+) patients, along with a comparative group of 333 normal controls (NCs). From the scans, we calculated the expression of DLBRP, AD-related pattern (ADRP) and Parkinson's disease-related pattern (PDRP) and compared them across groups. DLBRP scores were correlated with clinical measurements.Across independent cohorts, DLBRP robustly distinguished DLB from NCs (sensitivity >89
KW  - Humans
KW  - Lewy Body Disease: metabolism
KW  - Lewy Body Disease: diagnostic imaging
KW  - Male
KW  - Female
KW  - Aged
KW  - Positron-Emission Tomography
KW  - Cognitive Dysfunction: metabolism
KW  - Cognitive Dysfunction: diagnostic imaging
KW  - Brain: metabolism
KW  - Brain: diagnostic imaging
KW  - Fluorodeoxyglucose F18
KW  - Alzheimer Disease: metabolism
KW  - Alzheimer Disease: diagnostic imaging
KW  - Aged, 80 and over
KW  - Disease Progression
KW  - Biomarkers: metabolism
KW  - Prodromal Symptoms
KW  - Middle Aged
KW  - ALZHEIMER'S DISEASE (Other)
KW  - LEWY BODY DEMENTIA (Other)
KW  - PET, FUNCTIONAL IMAGING (Other)
KW  - Fluorodeoxyglucose F18 (NLM Chemicals)
KW  - Biomarkers (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:41344886
DO  - DOI:10.1136/jnnp-2025-336935
UR  - https://pub.dzne.de/record/285739
ER  -